Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): multicenter randomized study-Reference-Cited by-同舟云学术

Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): multicenter randomized study

Published:2019-01-01 Issue:6 Volume:34 Page:1002-1013
ISSN:0910-8327
Container-title:Heart and Vessels
language:en
Short-container-title:Heart Vessels

Author:

Kikuchi Shinnosuke,Tsukahara Kengo^ORCID,Sakamaki Kentaro,Morita Yukiko,Takamura Takeshi,Fukui Kazuki,Endo Tsutomu,Shimizu Makoto,Sawada Reimin,Sugano Teruyasu,Himeno Hideo,Kobayashi Syunichi,Arakawa Kentaro,Mochida Yasuyuki,Tsunematsu Takashi,Shigemasa Tomohiko,Okuda Jun,Ishikawa Toshiyuki,Kimura Kazuo,Tamura Kouichi

Funder

Bayer Yakuhin Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00380-018-01324-7.pdf

Reference35 articles.

1. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:2886–2891

2. Thambidorai SK, Parakh K, Martin DO, Shah TK, Wazni O, Jasper SE, Van Wagoner DR, Chung MK, Murray RD, Klein AL (2004) Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. Am J Cardiol 94:805–807

3. Borensztajn K, Peppelenbosch MP, Spek CA (2008) Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med 14:429–440